Molecular Diagnosis & Therapy, published by ADIS INT LTD, is a premier journal dedicated to the cutting-edge fields of genetics, molecular medicine, and pharmacology. With a strong emphasis on the translation of molecular insights into innovative therapeutic strategies, this journal serves as a vital resource for researchers, clinicians, and students aiming to stay at the forefront of medical and scientific advancements. The journal boasts an impressive standing in its categories, holding a Q1 ranking in Genetics, Medicine (miscellaneous), and Pharmacology, alongside a Q2 classification in Molecular Medicine for 2023, reflecting its influential contributions to the scientific community. Indexed in Scopus, it occupies distinct positions in its respective fields, ranked #77 in Genetics and Pharmacology, and #53 in Molecular Medicine, highlighting its robust impact factor and scholarly influence. Although it is not open access, the journal ensures widespread dissemination of valuable research, promoting enhanced understanding of molecular diagnostic techniques and therapeutic interventions. Since its inception in 2001, and continuing through to 2024, Molecular Diagnosis & Therapy remains an essential platform for disseminating vital research findings, fostering academic collaboration, and driving forward the dialogue in molecular diagnostics and treatment methodologies.

Molecular Genetics & Genomic Medicine, published by WILEY, is an esteemed and open-access journal that has been a prominent source of knowledge in the fields of genetics and molecular biology since its establishment in 2013. With an ISSN of 2324-9269, it aims to provide a platform for the dissemination of novel findings and innovative research that pushes the boundaries of genomics and its clinical applications. The journal holds a Q3 categorization in Genetics, Clinical Genetics, and Molecular Biology, reflecting its growing influence in these disciplines, as evidenced by its Scopus rankings. Researchers, professionals, and students alike will find valuable insights and advancements in genomic medicine, making this journal an essential resource for those dedicated to the understanding and application of genetic and molecular research in healthcare. Located at 111 River St, Hoboken, NJ, Molecular Genetics & Genomic Medicine continues to foster a global dialogue within the scientific community, ensuring accessible knowledge for all.

Cancer Biology & Medicine is a distinguished Open Access journal published by the China Anti-Cancer Association, dedicated to advancing research and understanding in the fields of Cancer Research and Oncology. Since its inception in 2012, the journal has provided a vital platform for the dissemination of high-quality research, evidenced by its impressive ranking within the Q1 and Q2 categories of oncology and cancer research as of 2023. With a significant impact factor and a Scopus ranking of #64 in Medicine/Oncology and #55 in Biochemistry, Genetics, and Molecular Biology, it plays a crucial role in shaping the future of cancer biology. By offering open access to its content, the journal ensures that pivotal research findings are readily available to researchers, professionals, and students globally, thereby fostering collaboration and innovation in cancer research. Situated in Tianjin, China, this journal is poised at the frontier of oncology research, making a significant impact through its rigorous peer-reviewed articles that address critical challenges in the field.

Advances in Pharmacological and Pharmaceutical Sciences is a premier open-access journal published by Hindawi Ltd. based in the United Kingdom. Established in 2020, the journal swiftly garnered attention for its commitment to disseminating high-quality research in the realms of pharmacology, toxicology, and pharmaceutical sciences. It holds a commendable impact with notable quartile rankings, including Q2 in both Organic Chemistry and Pharmacology, indicating its importance within these disciplines. By embracing an open-access model, the journal ensures that research findings are widely available, promoting increased visibility and collaboration among researchers, professionals, and students globally. With an ongoing convergence of insights projected through 2024, Advances in Pharmacological and Pharmaceutical Sciences aims to address critical issues and advancements in drug development and therapeutic practices, making it an invaluable resource for those at the forefront of scientific inquiry in pharmacology and related fields.

Theranostics is a premier journal in the field of Medicine and Pharmacology, published by IVYSPRING INT PUBL. With its commitment to open access since 2011, it facilitates the widespread dissemination of innovative research, fostering collaboration and advancements in therapeutic diagnostics. The journal proudly holds a Q1 ranking in both Medicine (Miscellaneous) and Pharmacology, Toxicology and Pharmaceutics, as of 2023, showcasing its esteemed position within the scientific community. Recognized globally, it ranks in the top 1%, with Scopus rankings placing it as 4th out of 398 in Medicine and 1st out of 43 in Pharmacology. Theranostics serves as a crucial platform for researchers, professionals, and students to explore cutting-edge developments as it converges multidisciplinary approaches to enhance patient care and treatment efficacy. With a focus on bridging experimental research and clinical applications, the journal is instrumental in shaping future therapies and diagnostic strategies.

Precision and Future Medicine is an esteemed academic journal published by Sungkyunkwan University School of Medicine, dedicated to advancing the fields of precision medicine and healthcare innovation. Established as an Open Access journal in 2017, it aims to disseminate cutting-edge research and insights that bridge the gap between basic and clinical sciences. With a focus on personalized medicine, genomics, and advanced therapeutic strategies, the journal serves as a vital resource for researchers, clinicians, and policy makers. Set in the dynamic environment of South Korea, Precision and Future Medicine provides a platform for the exchange of ideas that are shaping the future of medical science, thus contributing significantly to the global dialogue on health and wellness. As it continues to grow, the journal is committed to ensuring that high-quality research remains accessible to all, fostering a spirit of collaboration and innovation within the scientific community.

Pharmaceutical Medicine is a leading journal published by SPRINGER INT PUBL AG, dedicated to the field of pharmacology and pharmaceutical sciences. With ISSN 1178-2595 and E-ISSN 1179-1993, this journal serves as an essential platform for researchers and professionals to share groundbreaking findings and advancements in medication efficacy, safety, and innovative therapeutic strategies. Recognized for its contribution to the field, Pharmaceutical Medicine holds an impressive Q2 ranking in both Pharmacology and Medical Pharmacology categories, further underscored by its competitive Scopus rankings—positioned at 100/272 (63rd percentile) in Medical Pharmacology and 156/313 (50th percentile) in Pharmacology, Toxicology, and Pharmaceutics. Although it primarily operates on a traditional subscription basis, its robust academic reputation continues to attract a diverse readership worldwide. Addressed in the United Kingdom with facilities in Switzerland, the journal publishes authoritative articles from its inception in 2000 through to 2024, making it a pivotal resource for those seeking to enhance their understanding and application of pharmacological principles in clinical practice and research.

CURRENT GENE THERAPY is a leading journal in the field of gene therapy, offering a platform for researchers and professionals to publish their findings related to innovative approaches in gene-based treatments. Published by Bentham Science Publishers Ltd, this journal, with its ISSN 1566-5232 and E-ISSN 1875-5631, is indexed in respected databases, enhancing its visibility and impact in the scientific community. As of 2023, it holds a commendable impact factor, with categorized quartile rankings reflecting its influence, especially in Drug Discovery (Q2), Genetics (Q3), and Molecular Medicine (Q3). Although it follows a subscription model, the journal aims to bridge the gap between laboratory research and clinical applications, attracting submissions that provide critical insights into gene therapy advancements from 2001 to 2024. The editorial scope covers various aspects of gene therapy, including experimental studies and clinical trials, underlining its commitment to fostering knowledge that addresses genetic disorders and enhances therapeutic efficacy. Whether you are a researcher, clinician, or student, CURRENT GENE THERAPY serves as an invaluable resource at the forefront of genetic research and medical innovation.

Targeted Oncology is a premier, peer-reviewed journal published by SPRINGER, focusing on the latest advancements in the field of oncology, specifically targeting the development and application of targeted therapies. Since its inception in 2006, this journal has become an essential resource for researchers, healthcare professionals, and students, providing critical insights into innovative cancer treatments and the pharmacological landscape. Recognized for its impactful contributions, Targeted Oncology holds a distinguished Q1 ranking in both Oncology and Pharmacology categories as of 2023, underscoring its influence and relevance in the scientific community. With an impressive Scopus ranking reflecting its strong citation impact, the journal not only disseminates high-quality research but also facilitates knowledge exchange among oncologists and researchers working towards improving patient outcomes. Although not an Open Access journal, Targeted Oncology is committed to advancing cancer research and therapeutic strategies, making it an invaluable addition to the libraries of any institution dedicated to health and wellness.

Circulation-Genomic and Precision Medicine is a leading peer-reviewed journal published by Lippincott Williams & Wilkins, dedicated to advancing the fields of cardiology, cardiovascular medicine, and genetics. With an impressive impact factor and ranked in the Q1 quartile across multiple categories, including Cardiology and Genetics, this journal is pivotal for researchers and professionals seeking the latest insights and advancements in precision medicine. Established in 2018, it has rapidly gained recognition, evidenced by its commendable Scopus ranking and high percentiles among related fields. The journal emphasizes open access to enhance the dissemination of knowledge, making cutting-edge research readily available to a global audience. With the convergence of genomic science and cardiovascular health, Circulation-Genomic and Precision Medicine aims to foster interdisciplinary collaborations, offering a vital platform for innovative studies that impact patient care and clinical practices.